DRG Instruments Demonstrates DRG:HYBRID-XL Fully Automated Lab Analyzer

DRG Instruments GmbH (Marburg, Germany) demonstrated its fully automated random access analyzer, DRG:HYBRiD-XL, along with its newest ELISAs, at this year's MEDICA, the world's largest annual medical technology trade fair, that took place from 18-21 November in Düsseldorf, Germany. MEDICA provides the medical device industry with a central market for innovative products and systems that result in an important contribution to the efficiency and quality of patient care. The combination of product shows with international congresses, forums, as well as expert workshops, and the exchange of professional views make MEDICA a meeting point for international professionals from various fields in the medical sector.

DRG Instruments specializes in the development and production of innovative ELISAs and Chemiluminescent assays, both for routine and research applications, in the fields of diabetes diagnosis, endocrinology, prenatal/neonatal supervision, thyroid function and many more. Recently, DRG Instruments developed the world’s first nonradioactive immunoassays for the determination of active Renin and PLGF, as well as a complete panel of sensitive assays for the quantitative determination of saliva steroids. In the last five years, DRG Instruments has developed its own tumor marker panel and a broad range of ELISAS in the field of infectious diseases, including the world’s first assay for the qualitative detection of human Fasciola IgG.

At the MEDICA 2019 International Trade Fair, DRG demonstrated DRG:HYBRiD-XL, its fully automated, continuous access analyzer that allows the simultaneous measurement of immunoassays and clinical chemistry parameters, including turbidimetric tests, in one sample. It allows medical practitioners to carry out up to 40 tests of different types or 40 times of the same test, or up to 20-patient samples over a wide range of pre-packaged tests to serve different specialties.

Additionally, DRG presented several new DRG ELISAs, including Bordetella pertussis Toxin IgA/IgG (quantitative), Aspergillus fumigatus IgG/IgM and Bartonella Ab, at the event. The company also displayed its new and optimized SALIVA ELISAs: Unique Salivary Hepcidin and optimized Salivary Estradiol. The company’s saliva diagnostics products offer several benefits such as non-invasive sampling, measurement of the free (unbounded) fraction of steroids, and much higher diagnostic relevance with reproducible and reliable results, compared to serum analytics.

Related Links:
DRG Instruments GmbH